NYSE · AHealthcareLab Analytical Instruments

Agilent Technologies financials

$175.21+1.40%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Oct 31
FY24
Oct 31
FY23
Oct 31
FY22
Oct 31
FY21
Oct 31
FY20
Oct 31
FY19
Oct 31
FY18
Oct 31
FY17
Oct 31
FY16
Oct 31
Revenue$6.95B$6.51B$6.83B$6.85B$6.32B$5.34B$5.16B$4.91B$4.47B$4.20B
Gross profit$3.64B$3.54B$3.46B$3.72B$3.41B$2.84B$2.81B$2.68B$2.40B$2.20B
Gross margin52.4%54.3%50.7%54.4%53.9%53.1%54.3%54.5%53.6%52.3%
Operating income$1.48B$1.49B$1.35B$1.62B$1.35B$846.0M$941.0M$904.0M$807.0M$615.0M
Net income$1.30B$1.29B$1.24B$1.25B$1.21B$719.0M$1.07B$316.0M$684.0M$462.0M
Net margin18.8%19.8%18.1%18.3%19.1%13.5%20.7%6.4%15.3%11.0%
Diluted EPS$4.57$4.43$4.19$4.18$3.94$2.30$3.37$0.97$2.10$1.40
EBITDA$1.77B$1.75B$1.62B$1.94B$1.67B$1.15B$1.18B$1.11B$1.02B$861.0M
Operating cash flow$1.56B$1.75B$1.77B$1.31B$1.49B$921.0M$1.02B$1.09B$889.0M$793.0M
Free cash flow$1.15B$1.37B$1.47B$1.02B$1.30B$802.0M$866.0M$910.0M$713.0M$654.0M
Diluted shares285.0M291.0M296.0M300.0M307.0M312.0M318.0M325.0M326.0M329.0M

Balance sheet

Period endOct 31Oct 31Oct 31Oct 31Oct 31Oct 31
Cash & equivalents$1.79B$1.33B$1.59B$1.05B$1.48B$1.44B
Short-term investments$0.00$0.00$0.00$0.00$91.0M—
Total debt$3.35B$3.39B$2.73B$2.77B$2.73B$2.36B
Total assets$12.73B$11.85B$10.76B$10.53B$10.71B$9.63B
Total liabilities$5.99B$5.95B$4.92B$5.23B$5.32B$4.75B
Shareholders' equity$6.74B$5.90B$5.84B$5.30B$5.39B$4.87B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology